{"id":60776,"date":"2024-02-28T07:07:41","date_gmt":"2024-02-28T07:07:41","guid":{"rendered":"https:\/\/medsname.com\/tenvir-af\/"},"modified":"2026-05-21T05:27:39","modified_gmt":"2026-05-21T05:27:39","slug":"tenvir-af","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/tenvir-af\/","title":{"rendered":"Tenvir AF"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:16px 20px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin-top:0;\">Quick Answer &mdash; Tenvir AF (Tenofovir Alafenamide 25 mg)<\/h3>\n<ul>\n<li><strong>\u00da\u010dinn\u00e1 l\u00e1tka:<\/strong> tenofovir alafenamide fumarate (TAF) 25 mg, oral tablet, taken once daily with food.<\/li>\n<li><strong>Hlavn\u00ed indikace v tomto v\u00fdpisu:<\/strong> chronic hepatitis B virus (HBV) infection in adults &mdash; long-term suppression with substantially less kidney and bone exposure than older TDF.<\/li>\n<li><strong>Mechanismus \u00fa\u010dinku:<\/strong> nucleotide reverse-transcriptase inhibitor (NRTI). Same active metabolite as tenofovir disoproxil, but a different prodrug that releases tenofovir inside hepatocytes and lymphocytes.<\/li>\n<li><strong>Versus TDF:<\/strong> ~90% lower plasma tenofovir, ~6&ndash;7&times; higher intracellular drug. Same antiviral potency. Lower risk of renal toxicity and bone mineral density loss.<\/li>\n<li><strong>\u00da\u010dinnost proti HBV:<\/strong> non-inferior to TDF for HBV DNA suppression at 96 weeks; significantly better renal and bone safety markers in head-to-head trials.<\/li>\n<li><strong>Upozorn\u011bn\u00ed na vzplanut\u00ed HBV:<\/strong> severe acute exacerbation can occur on discontinuation. Never stop without specialist supervision.<\/li>\n<\/ul>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Co z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch <a href=\"https:\/\/medsbase.com\/cs\/reviews\/\">recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\"><strong>Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n<h3>Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n<p>Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n<h2 class=\"wp-block-heading\">What Is Tenvir AF?<\/h2>\n<p>Tenvir AF is an oral tablet containing <strong>tenofovir alafenamide fumarate 25 mg<\/strong> (TAF), manufactured by Cipla. Each pack typically contains 30 film-coated tablets.<\/p>\n<p>TAF is the second-generation prodrug of tenofovir, designed to fix the renal and bone toxicity issues seen with the older TDF (tenofovir disoproxil) prodrug. The originator brand is <strong>Vemlidy<\/strong> (Gilead, FDA-cleared for chronic hepatitis B in 2016). Same active drug as TDF, dramatically different pharmacokinetics.<\/p>\n<h2 class=\"wp-block-heading\">What Is Tenvir AF Used For?<\/h2>\n<ul>\n<li><strong>Chronic hepatitis B (CHB) in adults<\/strong> &mdash; first-line oral antiviral, especially in patients with chronic kidney disease (CKD), osteoporosis, age &gt; 60, or pre-existing TDF-related renal\/bone toxicity.<\/li>\n<li><strong>infekce HIV-1<\/strong> &mdash; component of combination regimens (most commonly co-formulated with FTC, dolutegravir or bictegravir, or rilpivirine). Not used as monotherapy in HIV.<\/li>\n<li><strong>HIV pre-expozi\u010dn\u00ed profylaxe (PrEP)<\/strong> &mdash; the TAF + emtricitabine combination (Descovy) is approved for PrEP in cisgender men and transgender women; TDF\/FTC remains preferred for at-risk people who could become pregnant.<\/li>\n<\/ul>\n<p>TAF is <strong>ne<\/strong> used to treat hepatitis C, herpes viruses, or any non-retroviral \/ non-HBV infection.<\/p>\n<h2 class=\"wp-block-heading\">Why TAF Instead of TDF?<\/h2>\n<p>TDF is rapidly hydrolysed in plasma to tenofovir, exposing the kidneys to high circulating drug levels for hours. TAF stays intact in plasma far longer because it is a more stable prodrug, and is preferentially activated by lymphocyte and hepatocyte intracellular esterases (cathepsin A, CES1). The net result:<\/p>\n<table style=\"border-collapse:collapse;width:100%;font-size:14px;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:8px;border:1px solid #ddd;text-align:left;\">Marker<\/th>\n<th style=\"padding:8px;border:1px solid #ddd;text-align:left;\">TDF 300 mg<\/th>\n<th style=\"padding:8px;border:1px solid #ddd;text-align:left;\">TAF 25 mg<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">Plasma tenofovir AUC<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">High (reference)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">~90% ni\u017e\u0161\u00ed<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border:1px solid #ddd;\">Intracellular TFV-DP in PBMCs<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Reference<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">~6&ndash;7&times; higher<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">eGFR decline at 96 wks (HBV)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Modest, dose-related<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Significantly less<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border:1px solid #ddd;\">Hip + spine BMD change<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Small reduction<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Less reduction; sometimes recovery on switch<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">Lipid effect<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Mildly favourable (lipid-lowering)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Mildly unfavourable (raises LDL\/HDL)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The lipid effect is the one trade-off. In patients with established cardiovascular disease, TDF may be preferred. For most HBV patients with renal or bone risk factors, TAF is the cleaner long-term option.<\/p>\n<h2 class=\"wp-block-heading\">Dosage and How to Take Tenvir AF<\/h2>\n<ul>\n<li><strong>Chronic hepatitis B:<\/strong> one 25 mg tablet once daily with food.<\/li>\n<li><strong>HIV (combination regimens):<\/strong> 25 mg if combined with non-boosted agents; 10 mg if combined with a CYP3A inhibitor (cobicistat, ritonavir).<\/li>\n<\/ul>\n<p>Take with food &mdash; bioavailability rises by approximately 65% with a moderate-fat meal. Swallow whole. Missed doses: take as soon as remembered if within 18 hours; otherwise skip and resume the next scheduled tablet.<\/p>\n<p><strong>Renal-impairment dose adjustment:<\/strong> no adjustment required for CrCl &ge; 15 mL\/min. Below 15 mL\/min, only use in patients on chronic haemodialysis (TAF dosed after dialysis on dialysis days). TAF is not recommended in non-dialysis end-stage renal disease.<\/p>\n<p><strong>Porucha funkce jater:<\/strong> no adjustment for mild or moderate; not recommended in decompensated cirrhosis (Child-Pugh C).<\/p>\n<h2 class=\"wp-block-heading\">Vedlej\u0161\u00ed \u00fa\u010dinky<\/h2>\n<p><strong>\u010cast\u00e9:<\/strong> headache (~10%), abdominal pain (~5%), fatigue, cough, nausea, back pain. Usually mild and self-limiting.<\/p>\n<p><strong>M\u00e9n\u011b \u010dast\u00e9, ale d\u016fle\u017eit\u00e9:<\/strong><\/p>\n<ul>\n<li><strong>Lipid changes<\/strong> &mdash; expect modest rise in LDL-C, HDL-C, total cholesterol, and triglycerides. Recheck lipids at 3 and 12 months. Consider statin therapy if cardiovascular risk is elevated.<\/li>\n<li><strong>P\u0159ib\u00fdv\u00e1n\u00ed na v\u00e1ze<\/strong> &mdash; HIV trials show several kg over 1&ndash;2 years on TAF-containing regimens vs TDF (regression of TDF&#8217;s mild lipid-lowering effect appears to drive part of this). Less established in HBV monotherapy.<\/li>\n<li><strong>Lactic acidosis with severe hepatomegaly<\/strong> &mdash; rare NRTI class effect; stop on unexplained progressive abdominal pain, rapid breathing, severe fatigue.<\/li>\n<li><strong>Severe acute hepatitis B exacerbation on stopping<\/strong> &mdash; same flare risk as TDF. Requires monitoring for at least 6 months after discontinuation.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Interakce s l\u00e9\u010divy<\/h2>\n<ul>\n<li><strong>Strong P-gp inducers<\/strong> &mdash; rifampicin, rifabutin, carbamazepine, phenytoin, oxcarbazepine, St John&#8217;s wort &mdash; lower TAF exposure. Avoid co-administration.<\/li>\n<li><strong>CYP3A inhibitors<\/strong> &mdash; cobicistat, ritonavir &mdash; significantly raise TAF exposure. Use the 10 mg form if co-administered with a boosted PI\/INSTI regimen.<\/li>\n<li><strong>Jin\u00e9 nefrotoxick\u00e9 l\u00e9ky<\/strong> &mdash; less of a concern than with TDF, but caution still advised with cidofovir, IV aminoglycosides, IV amphotericin B, high-dose NSAIDs.<\/li>\n<li><strong>Other tenofovir-containing products<\/strong> &mdash; do not combine TAF with TDF, adefovir, or another TAF-containing product.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Who Should Not Take Tenvir AF?<\/h2>\n<ul>\n<li>Known hypersensitivity to tenofovir alafenamide or any excipient<\/li>\n<li>Severe renal impairment (CrCl &lt; 15 mL\/min) not on chronic haemodialysis<\/li>\n<li>Decompensated cirrhosis (Child-Pugh C)<\/li>\n<li>Concurrent strong P-gp inducer where switching is not feasible<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Skladov\u00e1n\u00ed<\/h2>\n<p>Store below 30&deg;C in the original bottle with desiccant. Protect from moisture. Keep out of reach of children.<\/p>\n<h2 id=\"faqs\">\u010casto kladen\u00e9 dotazy<\/h2>\n<h3 class=\"wp-block-heading\">Is Tenvir AF the same as Vemlidy?<\/h3>\n<p>Yes &mdash; same molecule (tenofovir alafenamide 25 mg), same indication (chronic hepatitis B), same once-daily dosing. Tenvir AF is Cipla&#8217;s licensed generic version. Vemlidy is the originator (Gilead).<\/p>\n<h3 class=\"wp-block-heading\">If TAF is better, why does anyone still take TDF?<\/h3>\n<p>Several reasons: TDF has a 20-year safety database; TDF lowers LDL cholesterol slightly (TAF does the opposite); pregnancy data is more mature for TDF; and TDF is materially cheaper. For young patients without renal or bone issues, TDF remains a perfectly reasonable first-line choice. TAF is preferred when renal or bone safety matters most.<\/p>\n<h3 class=\"wp-block-heading\">Can I switch from Tenvir (TDF) to Tenvir AF?<\/h3>\n<p>Yes, and many patients do, especially after years on TDF when small declines in eGFR or BMD become relevant. The switch is straightforward: stop TDF, start TAF the next day. Antiviral suppression is maintained because both deliver the same active metabolite. Renal markers usually improve within 3&ndash;6 months. Recheck eGFR, urine protein, phosphate at 3 months post-switch.<\/p>\n<h3 class=\"wp-block-heading\">Will Tenvir AF cure my hepatitis B?<\/h3>\n<p>No oral antiviral cures HBV. Tenofovir alafenamide suppresses replication so completely that viral DNA usually becomes undetectable and liver inflammation resolves &mdash; but the cccDNA template inside hepatocytes is not eliminated. Around 1&ndash;3% of patients per year achieve functional cure (HBsAg loss). For most patients, treatment is long-term.<\/p>\n<h3 class=\"wp-block-heading\">Should I expect weight gain on Tenvir AF?<\/h3>\n<p>HIV combination data show modest weight gain on TAF regimens vs TDF, of around 2&ndash;4 kg over 96 weeks. The effect is smaller in HBV monotherapy and is partly explained by reversal of TDF&#8217;s slight metabolic disadvantage. If weight gain is concerning, baseline lipid and glucose monitoring is reasonable.<\/p>\n<h3 class=\"wp-block-heading\">Can I take Tenvir AF in pregnancy?<\/h3>\n<p>Pregnancy data for TAF is growing but is still less mature than for TDF. For HBV in late pregnancy (week 28+) to prevent vertical transmission, TDF is the preferred choice based on the larger safety database. If you are stable on TAF and become pregnant, discuss with your hepatologist before switching &mdash; the call depends on viral load, fibrosis stage, and trimester.<\/p>\n<h3 class=\"wp-block-heading\">Is Tenvir AF active against HIV resistance mutations?<\/h3>\n<p>TAF and TDF have an identical resistance profile because they deliver the same active metabolite. Both retain activity against most thymidine-analogue mutations (TAMs) but are reduced in efficacy against the K65R reverse-transcriptase mutation. Resistance testing should guide regimen choice when available.<\/p>\n<h3 class=\"wp-block-heading\">Do I need any blood tests before starting Tenvir AF?<\/h3>\n<p>Yes &mdash; baseline HBV DNA, HBeAg \/ anti-HBe, HBsAg, ALT\/AST, full blood count, eGFR, urinalysis (proteinuria), serum phosphate, lipid panel, and HIV antibody\/antigen test. Treatment monitoring then settles to every 3&ndash;6 months for stable patients.<\/p>\n<h3 class=\"wp-block-heading\">Does Tenvir AF interact with statins, blood-pressure drugs, or contraception?<\/h3>\n<p>No clinically significant interaction with statins, ACE inhibitors, ARBs, beta-blockers, calcium-channel blockers, or hormonal contraception. The few real interactions are with strong P-gp inducers (rifampicin, anticonvulsants) and CYP3A boosters (cobicistat, ritonavir).<\/p>\n<h3 class=\"wp-block-heading\">Where can I order Tenvir AF?<\/h3>\n<p>You can order Tenvir AF directly from MedsBase. We supply genuine Cipla stock with worldwide shipping. Treatment of chronic hepatitis B should be supervised by a hepatologist or gastroenterologist with HBV DNA, ALT, eGFR, and HBsAg\/anti-HBs monitoring at appropriate intervals.<\/p>\n<h2 class=\"wp-block-heading\">Odm\u00edtnut\u00ed odpov\u011bdnosti<\/h2>\n<p>The information on this page is for educational purposes and is not a substitute for professional medical advice. Treatment of chronic hepatitis B and HIV requires baseline workup, ongoing specialist monitoring, and individualised regimen choice. Do not start, stop, or switch tenofovir-based therapy without consulting a qualified clinician.<\/p>\n<p class=\"medsbase-bundle-link-2026-05-01\" data-marker=\"mb-bundle-link-prep-starter-pack\">Tenvir-AF (TAF\/FTC) handles HIV PrEP but does not cover bacterial STIs; if you&#8217;d like layered protection many users pair it with doxy-PEP \u2014 our <a href='\/cs\/prep-starter-pack\/'>PrEP Starter Pack (Tenvir-EM + doxycyklin 100 mg)<\/a> bundles the established TDF\/FTC PrEP regimen with doxycycline for syphilis, chlamydia, and gonorrhoea prevention.<\/p>\n<p class=\"medsbase-link-boost-2026-05-08\" data-marker=\"mb-link-boost-tenvir-em\">Pacienti u\u017e\u00edvaj\u00edc\u00ed <a href=\"https:\/\/medsbase.com\/cs\/tenvir-af\/\">Tenvir AF<\/a> for hepatitis B who also require HIV pre-exposure prophylaxis should note that <a href=\"https:\/\/medsbase.com\/cs\/tenvir-em\/\">Tenvir EM (tenofovir disoproxil fumar\u00e1t 300 mg + emtricitabin 200 mg)<\/a> is the approved dual-component PrEP regimen combining TDF with emtricitabine for comprehensive HIV prevention.<\/p>\n<p class=\"medsbase-link-boost-2026-05-10\" data-marker=\"mb-link-boost-avonza\">Clinics building ART formularies around <a href=\"https:\/\/medsbase.com\/cs\/tenvir-af\/\">Tenvir AF (tenofovir alafenamide 25 mg)<\/a> as a renal-sparing backbone also stock <a href=\"https:\/\/medsbase.com\/cs\/avonza\/\">Avonza (TDF \/ lamivudine \/ efavirenz)<\/a> for cost-conscious patients in whom the older TDF formulation&#8217;s renal profile is clinically acceptable.<\/p>\n<p class=\"medsbase-link-boost-2026-05-21\" data-marker=\"mb-link-boost-tavin-em\">Patients tolerating <a href=\"https:\/\/medsbase.com\/cs\/tenvir-af\/\">Tenvir AF (tenofovir alafenamide 25 mg)<\/a> but seeking a lower-cost daily PrEP option without the TAF\/FTC premium may consider <a href=\"https:\/\/medsbase.com\/cs\/tavin-em\/\">Tavin EM (tenofovir disoproxil 300 mg + emtricitabin 200 mg)<\/a>, the older TDF\/FTC PrEP backbone with the largest evidence base.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Souvisej\u00edc\u00ed alternativy<\/h3>\n<p>Dal\u0161\u00ed produkty v <strong>Chronick\u00e1 onemocn\u011bn\u00ed<\/strong> kter\u00e9 z\u00e1kazn\u00edci tak\u00e9 prohl\u00ed\u017eej\u00ed:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/cs\/ebasil\/\">Ebasil<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/budecort-inhaler\/\">Budecort Inhaler<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/fluvoxin\/\">Fluvoxin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/arkamin-h\/\">Arkamin-H<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/ivepred\/\">Ivepred<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 L\u00e9\u010d\u00ed infekci HIV<br \/>\n\u2705 Sni\u017euje virovou n\u00e1lo\u017e<br \/>\n\u2705 Protects kidneys<br \/>\n\u2705 Decreases bone loss<br \/>\n\u2705 Zlep\u0161uje kvalitu \u017eivota<\/p>\n<p><strong>Tenvir AF<\/strong> obsahuje <strong>Tenofovir<\/strong> <strong>Alafenamide<\/strong>.<\/p>","protected":false},"featured_media":60777,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3334,3304],"product_tag":[3335,4920,4921],"class_list":{"0":"post-60776","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-hepatitis-medication","9":"product_cat-hiv-medication","10":"product_tag-tenofovir","11":"product_tag-tenofovir-alafenamide","12":"product_tag-tenvir-af","14":"first","15":"instock","16":"shipping-taxable","17":"purchasable","18":"product-type-variable","19":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product\/60776","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/comments?post=60776"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media\/60777"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media?parent=60776"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_brand?post=60776"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat?post=60776"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_tag?post=60776"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}